-
SGLT 関連製品 (27)
関連製品 (27)
- 1
- 2
-
Empagliflozin-d4
0 Images別名: BI 10773-d4Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
-
SGLT2-IN-2
0 Images製品番号: HY-174400純度: 99.57%SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice.
-
Rongliflozin
0 Images製品番号: HY-153113CAS 番号: 2648020-91-9別名: DJT1116PGRongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM).
-
SGLT inhibitor-1
0 Images製品番号: HY-112807CAS 番号: 2247314-23-2SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively.
-
SGL5213
0 Images製品番号: HY-114308CAS 番号: 1240305-17-2SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment.
-
Ertugliflozin-d9
0 Images製品番号: HY-15461S1別名: PF-04971729-d9Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
-
Canagliflozin-d6
0 Images製品番号: HY-10451S2別名: JNJ 28431754-d6Canagliflozin-d6 is the deuterium labeled Canagliflozin. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
-
SGLT1/2-IN-2
0 Images製品番号: HY-145357CAS 番号: 2387812-73-7
-
Empagliflozin-d8
0 Images製品番号: HY-166652SCAS 番号: 2714418-84-3Empagliflozin-d8 is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
-
BI-44847
0 Images製品番号: HY-117075CAS 番号: 421592-30-5BI-44847 is a selective and orally active SGLT2 inhibitor. BI-44847 can increase UGE and decrease HbA1c levels. BI-44847 shows improvement in fasting and fed glucose levels. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM).
-
Mizagliflozin (sebacate)
0 Images製品番号: HY-17638ACAS 番号: 1169392-27-1別名: DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models.
-
Dapagliflozin methyl acetate
0 Images製品番号: HY-Z0437CAS 番号: 1632287-34-3Dapagliflozin methyl acetate is an orally active SGLT2 inhibitor. Dapagliflozin methyl acetate may be used in type 2 diabetes research.
-
Sotagliflozin (Standard)
0 Images別名: LX-4211 (Standard); LP-802034 (Standard)Sotagliflozin (Standard) is the analytical standard of Sotagliflozin. This product is intended for research and analytical applications. Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
-
HSK0935 (Standard)
0 Images製品番号: HY-101782RCAS 番号: 1638851-44-1HSK0935 (Standard) is the analytical standard of HSK0935 (HY-101782). This product is intended for research and analytical applications. HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
-
Velagliflozin proline hydrate (Standard)
0 Images製品番号: HY-109018BRCAS 番号: 1661838-94-3Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
-
Enavogliflozin (Standard)
0 Images製品番号: HY-109144RCAS 番号: 1415472-28-4別名: DWP-16001 (Standard)Enavogliflozin (Standard) is the analytical standard of Enavogliflozin (HY-109144). This product is intended for research and analytical applications. Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
-
SGLT2-IN-1 (Standard)
0 Images製品番号: HY-I1120RCAS 番号: 864070-37-1SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin.
-
Licogliflozin (Standard)
0 Images製品番号: HY-109092RCAS 番号: 1291094-73-9別名: LIK066 (Standard)Licogliflozin (Standard) is the analytical standard of Licogliflozin (HY-109092). This product is intended for research and analytical applications. Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
- 1
- 2
